EGFR tyrosine kinase inhibitors (EGFR-TKIs) are the standard first-line (1L) treatment in advanced EGFR-mutant NSCLC possessing Ex19del or 21 L858R mutants (6). Here, EGFR is linked to non-small cell lung carcinoma.